Federated Investors Inc. PA acquired a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 148,211 shares of the biopharmaceutical company’s stock, valued at approximately $1,304,000. Federated Investors Inc. PA owned 0.21% of Sangamo Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SGMO. Granahan Investment Management Inc. MA raised its stake in Sangamo Therapeutics by 333.3% during the 1st quarter. Granahan Investment Management Inc. MA now owns 1,032,859 shares of the biopharmaceutical company’s stock valued at $5,371,000 after purchasing an additional 794,508 shares during the last quarter. United Services Automobile Association acquired a new position in Sangamo Therapeutics during the 1st quarter valued at $1,394,000. Vanguard Group Inc. raised its stake in Sangamo Therapeutics by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 3,087,650 shares of the biopharmaceutical company’s stock valued at $16,056,000 after purchasing an additional 239,544 shares during the last quarter. Iguana Healthcare Management LLC acquired a new position in Sangamo Therapeutics during the 1st quarter valued at $780,000. Finally, Parametric Portfolio Associates LLC acquired a new position in Sangamo Therapeutics during the 1st quarter valued at $578,000. 63.43% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) opened at 13.90 on Friday. The stock has a 50 day moving average of $10.95 and a 200-day moving average of $7.54. Sangamo Therapeutics, Inc. has a 52 week low of $2.65 and a 52 week high of $15.05. The firm’s market cap is $1.16 billion.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The company had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $5.82 million. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. Sangamo Therapeutics’s quarterly revenue was up 124.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.38) earnings per share. Analysts expect that Sangamo Therapeutics, Inc. will post ($0.82) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Federated Investors Inc. PA Takes $1.30 Million Position in Sangamo Therapeutics, Inc. (SGMO)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/15/federated-investors-inc-pa-takes-1-30-million-position-in-sangamo-therapeutics-inc-sgmo.html.

Several equities analysts recently commented on SGMO shares. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Friday, August 18th. Jefferies Group LLC reiterated a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research note on Thursday. Piper Jaffray Companies set a $8.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Thursday, August 10th. ValuEngine upgraded shares of Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $30.00 target price (up from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $14.40.

In other news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the sale, the vice president now owns 35,517 shares of the company’s stock, valued at $355,170. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Curt A. Herberts III sold 11,474 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $10.44, for a total transaction of $119,788.56. Following the completion of the sale, the vice president now directly owns 23,991 shares of the company’s stock, valued at approximately $250,466.04. The disclosure for this sale can be found here. In the last three months, insiders sold 41,474 shares of company stock valued at $494,789. 8.10% of the stock is currently owned by company insiders.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.